Article Information
vol. 12 no. 565
- Received for publication January 24, 2020
- Accepted for publication September 4, 2020
- .
Author Information
- Anusha Kalbasi1,2,3,*,
- Mito Tariveranmoshabad1,†,
- Kevin Hakimi1,†,
- Sarah Kremer1,
- Katie M. Campbell4,
- Juan M. Funes2,
- Agustin Vega-Crespo4,
- Giulia Parisi4,
- Ameya Champekar4,
- Christine Nguyen1,
- Davis Torrejon4,
- Daniel Shin4,
- Jesse M. Zaretsky4,
- Robert D. Damoiseaux3,5,6,
- Daniel E. Speiser7,
- Pedro P. Lopez-Casas8,
- Marisol Quintero8 and
- Antoni Ribas2,3,4,5,9
- 1Department of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.
- 2Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.
- 3Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
- 4Division of Hematology-Oncology, Department of Medicine, UCLA, Los Angeles, CA 90095, USA.
- 5Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.
- 6California NanoSystems Institute, UCLA, Los Angeles, CA 90095, USA.
- 7Department of Oncology, University of Lausanne, 1015 Lausanne, Switzerland.
- 8Highlight Therapeutics, Paterna 46980 (Valencia), Spain.
- 9Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
- ↵*Corresponding author. Email: anushakalbasi{at}mednet.ucla.edu